



## ROCA® - A New Surveillance Test for Ovarian Cancer

The ROCA Test is a blood test for women who are concerned about their risk of ovarian cancer. The test is intended for women over 35 years who carry a mutation in the *BRCA1*, *BRCA2* or other genes related to ovarian cancer<sup>1</sup>.

Women with a *BRCA1* or *BRCA2* pathogenic mutation have a high lifetime risk of developing ovarian cancer and are generally advised to consider preventative surgery (removal of both ovaries and fallopian tubes). For women who cannot undergo preventative surgery or decide to delay the procedure to preserve fertility and avoid early menopause, the ROCA Test represents a viable surveillance option.

### How the ROCA Test works


The ROCA Test uses an algorithm that analyses CA-125 levels, age, and menopausal status to provide a risk of having ovarian cancer. The risk result is categorized into one of 3 categories :

- **NORMAL:** Routine test in 4 months
- **INTERMEDIATE:** Early repeat test in 6 weeks
- **ELEVATED:** Repeat test plus transvaginal ultrasound (TVUS) within 6 weeks.

### Evidence behind the ROCA Test

- Proven through three prospective trials in 8564 high risk women<sup>2,3,4</sup>
- High performance: Sensitivity 86%, Specificity 99%; PPV 43%; NPV 99%.<sup>2</sup>
- The only test proven to detect ovarian cancer earlier, reducing late-stage diagnoses.<sup>4</sup>
- Fewer women needing neo-adjuvant chemotherapy before surgery (p=0.008).<sup>2</sup>
- More cases detected when TVUS is normal (P=0.01vs annual CA-125).<sup>3</sup>
- Up to 50% of case are detected when CA-125 is <35U/ml.<sup>3,4</sup>

### Significant Reduction in Late-Stage Ovarian Cancer cases due to Surveillance using the ROCA Test



Cases detected at stages greater than 3a, no surveillance compared to ROCA surveillance every 4 months. Error bars denote 95% confidence intervals. Adapted and reproduced by permission of the authors.<sup>4</sup>

### Accessing the ROCA test in 4 easy steps

1



#### Consultation

Patient Consultation

2



#### Sample Collection

Blood sample taken

3



#### CA 125 Test

Serum Prep  
CA<sub>125</sub> Test Result

4



#### Roca® Algorithm

CA<sub>125</sub> Test Result  
Menopausal Status Age



**GENESUPPORT**  
genetics & health

**Pricing** CHF 150.- (payable by the patient)

**Sampling** Serum-gel tube, volume 5 ml  
Store at room temperature

**Contact** PD Dr med. Bernard Conrad  
FMH Medical Genetics  
✉ [bernard.conrad@genesupport.ch](mailto:bernard.conrad@genesupport.ch)

PD PhD Frédérique Sloan Béna  
FAMH Medical Genetics  
✉ [frederique.sloanbena@genesupport.ch](mailto:frederique.sloanbena@genesupport.ch)

Dr PhD Christophe Cordier  
Genetic Counsellor  
✉ [christophe.cordier@medisyn.ch](mailto:christophe.cordier@medisyn.ch)

## Literature

- <sup>1</sup> NICE (UK) guideline [NG241]: Ovarian cancer: identifying and managing familial and genetic risk. NICE recommends the ROCA Test for women with pathogenic mutations in BRCA1 (>35 years old), BRCA2 (>40 years old), and RAD51C, RAD51D, BRIP1 and PALB2 (>45 years old)
- <sup>2</sup> Rosenthal, AN, et al. J. Clin. Oncol. 35(13): 1411-1420, 2017
- <sup>3</sup> Skates, SJ, et al. Clin. Cancer Res. 23(14): 3628- 3637, 2017
- <sup>4</sup> Philpott, S et al. J Med Genet. 60(5):440-449, 2023.

ROCA® (Risk of Ovarian Cancer Algorithm) is a registered trademark of GENinCode Plc in the UK, European Union and in the United States